Protocol digest of a randomized phase III trial comparing S-1-based chemoradiotherapy with/without nivolumab for unresectable locally advanced or borderline resectable pancreatic cancer: JCOG1908E (PENETRATE)
Japanese Journal of Clinical Oncology · 2024
DOI: 10.1093/jjco/hyae084 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Japanese Journal of Clinical Oncology, 2024. Verfasst von Yusuke Sano und 10 weiteren Autor:innen. Beteiligte Einrichtung: Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo 104-0045, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Chemoradiotherapy, Drug Combinations, Nivolumab. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Pancreatic cancer remains a highly lethal disease with a 5-year survival proportion of <10%. Chemoradiotherapy is a treatment option for unresectable locally advanced (UR-LA) or borderline resectable (BR) pancreatic cancer, but its efficacy is not sufficient. Induction of the synergistic effect of irradiation and immune checkpoint inhibitors can be an attractive strategy. An open-label randomized phase III trial has been conducted since October 2020 to confirm the superiority of nivolumab plus S-1-based chemoradiotherapy over S-1-based chemoradiotherapy alone in patients with UR-LA or BR pancreatic cancer. A total of 216 patients will be enrolled in 14 institutions within 3.5 years. The primary endpoint of the safety run-in part is dose-limiting toxicity, and that of the phase III part is overall survival. This trial was registered at the Japan Registry of Clinical Trials as jRCT2080225361 (https://jrct.niph.go.jp/latest-detail/jRCT2080225361).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo 104-0045, Japan.
- Cancer Treatment Center, Kansai Medical University Hospital, Osaka 573-1191, Japan.
- Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan.
- Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.
- Department of Radiation Oncology, Showa University School of Medicine, Tokyo 142-8666, Japan.
- Department of Gastroenterology, Kanagawa Cancer Center, Yokohama 241-8515, Japan.
ORCID-Profile: Yusuke Sano, Keita Sasaki
Zitieren
APA
Sano, Y., Kanai, M., Morizane, C., Sasaki, K., Yoshimura, M., Ito, Y., Furuse, J., Ozaka, M., Fukuda, H., Ueno, M., & Hepatobiliary and Pancreatic Oncology Group in Japan Clinical Oncology Group (2024). Protocol digest of a randomized phase III trial comparing S-1-based chemoradiotherapy with/without nivolumab for unresectable locally advanced or borderline resectable pancreatic cancer: JCOG1908E (PENETRATE). Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyae084
Vancouver
Sano Y, Kanai M, Morizane C, Sasaki K, Yoshimura M, Ito Y, et al. Protocol digest of a randomized phase III trial comparing S-1-based chemoradiotherapy with/without nivolumab for unresectable locally advanced or borderline resectable pancreatic cancer: JCOG1908E (PENETRATE). Japanese Journal of Clinical Oncology. 2024. doi:10.1093/jjco/hyae084
BibTeX
@article{Sano2024,
author = {Sano, Yusuke and Kanai, Masashi and Morizane, Chigusa and Sasaki, Keita and Yoshimura, Michio and Ito, Yoshinori and Furuse, Junji and Ozaka, Masato and Fukuda, Haruhiko and Ueno, Makoto and Hepatobiliary and Pancreatic Oncology Group in Japan Clinical Oncology Group, Hepatobiliary and Pancreatic Oncology Group in Japan Clinical Oncology Group},
title = {Protocol digest of a randomized phase III trial comparing S-1-based chemoradiotherapy with/without nivolumab for unresectable locally advanced or borderline resectable pancreatic cancer: JCOG1908E (PENETRATE)},
journal = {Japanese Journal of Clinical Oncology},
year = {2024},
doi = {10.1093/jjco/hyae084}
}
EUVIMED